CD21low B cells in systemic sclerosis: A possible marker of vascular complications

Clin Immunol. 2020 Apr:213:108364. doi: 10.1016/j.clim.2020.108364. Epub 2020 Feb 19.

Abstract

Objectives: To evaluate expansion of CD21low B cells and their role in B cell homeostasis, apoptosis, clinical manifestations and serum vascular endothelial growth factor (VEGF) in systemic sclerosis (SSc).

Materials and methods: B-cells subpopulations and apoptosis have been assessed in 74 SSc patients and 20 healthy donors. Renal Doppler ultrasound, echocardiography, pulmonary function test and VEGF were performed.

Results: SSc patients with expanded CD21low B cells (SSc-CD21low) show a distinct B cell profile with increased memory B cells compared to patients without CD21low B cells (SSc-CD21+). Renal resistive index, systolic pulmonary arterial pressure and FVC/DLCO ratio were significantly higher in SSc-CD21low group than SSc-CD21+, DLCO was lower in SSc-CD21low group than SSc-CD21+. We found a positive linear correlation between CD21low and sPAP, RI and FVC/DLCO ratio whereas a negative correlation was observed between CD21low and DLCO and VEGF levels.

Conclusions: CD21low B cells are increased in SSc patients with visceral vascular manifestations.

Keywords: B cells; CD21(low); Kidney; Pulmonary arterial hypertension; Systemic sclerosis.

MeSH terms

  • Aged
  • B-Lymphocyte Subsets / immunology*
  • Female
  • Heart Diseases / etiology
  • Humans
  • Kidney Diseases / etiology
  • Lung Diseases / etiology
  • Male
  • Middle Aged
  • Receptors, Complement 3d / immunology
  • Scleroderma, Systemic / complications*
  • Scleroderma, Systemic / immunology*
  • Scleroderma, Systemic / pathology
  • Vascular Diseases / etiology*
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Receptors, Complement 3d
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A